Allarakhia M., 2011, Novartis Institutes for Biomedical Research, @CanBiotech Inc.
Bianchi M., 2011, Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis, Technovation, 31, 22-33.
Castells M., 2001, The Internet Galaxy: Reflections on the Internet, Business, and Society, Oxford: Oxford University Press.
Chesbrough H., 2003, Open Innovation. The New Imperative for Creating and Profiting from Technology, Boston: Harvard Business School Press.
Chesbrough H., 2006, Open Innovation: A New Paradigm for Understanding Industrial Innovation, W: Open Innovation Researching a New Paradigm, red. H. Chesbrough, W. Vanhaverbeke, J. West, Oxford: Oxford University Press.
Chesbrough H., 2010, Open Services Innovation, Rethinking Your Busines to Grow and Compete in a New Era, New York: John Wiley & Sons.
Comer B., 2010, GSK signed the most in-license drug deals in '08-'09, Medical Marketing & Media, April, www.scmagazine.com/gsk-signed-the-most-in-license-drug-deals-in-08-09/article/ 168387/ [dostęp 20.02.2017].
Czetwertyński S., 2012, Produkcja partnerska w internecie jako przykład globalnej dezintegracji procesu produkcji, W: Ekonomia i prawo. Procesy integracyjne we współczesnej gospodarce. Część V. Integracja i dezintegracja w sektorze realnym, red. B. Polszakiewicz, J. Boehlke, Toruń: Wyd. UMK.
Edwards M., Murray F., Yu R., 2010, Value Creation and Sharing Among Universities, Biotechnology and Pharma, https://rolph.recap.com/signalsmag.nsf/0/C233187B7556141E88256D8700658B E9/$file/Value_Creation0603.pdf [dostęp: 20.02.2017].
Hardin G., 1968, The Tragedy of the Commons, Science, 162, 1243-1248, doi:10.1126/science. 162.3859.1243.
Hedner T., 2012, Change in the Pharmaceutical Industry. Aspects on Innovation, Entrepreneurship, Openness, and Decision Making, Linköping Studies in Science and Technology, Dissertations, no. 1393, Linköping: Linköping University Electronic Press.
Herzog Ph., 2011, Open and Closed Innovation. Different Cultures for Different Strategies, Wiesbaden: Gabler Research.
Hippel E. von, 2002, Open source projects as horizontal innovation networks - by and for users, MIT Sloan School of Management Working Paper No. 4366-02 June.
Kelly K., 2001, Nowe reguły nowej gospodarki. Dziesięć nowych strategii biznesowych dla świata połączonego siecią, Warszawa: WIG Press.
Lee N. i in., Interfacing Intellectual Property Rights and Open Innovation, www.wipo.int/edocs/ mdocs/mdocs/en/wipo_ipr_ge_11/wipo_ipr_ge_11_topic6.pdf [dostęp 20.02.2017].
Levy H.V., 2011, The Transformation of Basic Research Into Commercial Value: Economic Aspects and Practical Issues, Journal of Entrepreneurship, Management and Innovation, 7, 4-15.
Merges R.P., 1996, Contracting into Liability Rules: Intellectual Property Rights and Collective Rights Organizations, California Law Review, 1293, http://scholarship.law.berkeley.edu/californialawreview/ vol84/iss5/1 [dostęp: 20.02.2017].
Novartis Repository, http://oak.novartis.com [dostęp 20.02.2017].
Ostrom E., 1990, Governing the Commons: The Evolution of Institutions for Collective Action, Cambridge: Cambridge University Press.
Pohulak-Żołędowska E., 2010, In Finding Sources of Innovation - Transformation of Universities, W: Policies for Improving Growth Potential of Economy: International Perspective, red. A.P. Balcerzak, Toruń: Wyd. UMK.
Pohulak-Żołędowska E., 2011, Knowledge Production: Industrial Science as a Source of Economies Innovations, Wrocław University of Economics, Argumenta Oeconomica, 19(26), 284-296.
Pohulak-Żołędowska E., 2013, Industrial Meaning of University Basic Research in Modern Economies, Managerial Economics, 14, 137-150.
Roy A. i in., 2010, Open access high throughput drug discovery in the public domain: a Mount Everest in the making, Current Pharmaceutical Biotechnology, 11(7), 764-778.
Roy A. i in., 2011, Recent Trends in Collaborative, Open Source Drug Discovery, The Open Conference Proceedings Journal, http://benthamscience.com/open/toprocj/articles/V002/130 TOPROCJ.pdf [dostęp 20.02.2017].
Waguespack D.M., Fleming L., 2009, Scanning the Commons? Evidence on the Benefits to Startups Participating in Open Standards Development, Management Science, 55(2), 210-223.
Waldron R.F., 2012, Open Innovation in Pharma - Defining Dialogue, www.pharmexec.com/pharmexec/ article/articleDetail.jsp?id=788391&pageID=1&sk=&date= [dostęp: 20.02.2017].